Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 641-644

  Bottecchia, Marcelle ^a   Madejón, Antonio ^a   Puente, Sabino ^a   García Samaniego, Javier ^a   Rivas, Pablo ^a   Herrero, Dolores ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Africa; HBV; HBV genotypes; Lamivudine

Indexed keywords

HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHIONINE; VALINE; VIRUS DNA;

ADOLESCENT; ADULT; AFRICA; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CODON; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MUTATIONAL ANALYSIS; SPAIN; VIRAL GENETICS; VIRUS DETECTION; VIRUS GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, VIRAL; EMIGRANTS AND IMMIGRANTS; FEMALE; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; SPAIN; YOUNG ADULT;

EID: 79951535550     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq484     Document Type: Article

References (22)

1. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B infection. Int J Med Sci 2005; 2: 50-7.
2. Te H, Jensen D. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 Suppl 1: S1-3.
4. Echevarría JM, Avellón A, Magnius L. Molecular epidemiology of hepatitis B virus in Spain: identification of viral genotypes and prediction of antigenic subtypes by limited sequencing. J Med Virol 2005; 76: 176-84.
5. Bottecchia M, Souto F, Ó Km et al. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiol 2008; 8: 11.
6. Bottecchia M, Madejón A, Sheldon J et al. Hepatitis B virus genotype A2 harbours an L271R polymorphism which may account for a lower response to adefovir. J Antimicrob Chemother 2008; 62: 626-7.
7. Palumbo E, Scotto G, Faleo G et al. Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis. Arq Gastroenterol 2007; 44: 54-7.
8. Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Infect Ther 2004; 2: 853-71.
9. Thompson A, Ayers A, Yuen L et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2007; 22: 1078-85.
10. Liu C, Kao J. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008; 13: 613-24.
11. Lok A, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
12. Treviño A, Soriano V, Madejón A et al. Transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. AIDS Res Human Retroviruses 2009; 25: 1273-6.
13. Ludwig A, Goebel T, Adams O et al. Primary resistance mutations against nucleos(t)ide analogues in treatment naïve patients with HBV infection. In: Abstracts of the Fiftieth Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 884, p. 701. American Association for the Study of Liver Diseases, Alexandria, VA, USA.
14. Fung S, Mazulli T, El-Kashab M et al. Lamivudine-resistant mutation among treatment-naive hepatitis B patients is common and may be associated with treatment failure. In: Abstracts of the Fiftieth Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 888, p. 703. American Association for the Study of Liver Diseases, Alexandria, VA, USA.
15. Hoffmann C, Charalambous S, Martin D et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47: 1479-85.
16. Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis 2008; 47: 1486-9.
17. Matthews G, Bartholomeusz A, Locarnini S et al. Characteristics of drug-resistant HBV in an international collaborative study of HIV-HBV infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-70.
18. Manzardo C, Treviño B, Gómez J et al. Communicable disease in immigrant population attended to in a tropical medicine unit: epidemiological aspects and public health issues. Travel Med Infect Dis 2008; 6: 4-11.
19. Monge-Maillo B, Jiménez C, Pérez-Molina JA et al. Imported infectious disease in mobile populations, Spain. Emerg Infect Dis 2009; 15: 1745-52.
20. Pérez-Molina JA, Herrero-Martínez JM, Norman F et al. Clinical, epidemiological characteristics and implications for liver biopsy and treatment in immigrants with chronic hepatitis B at a referral hospital in Madrid. J Viral Hepat 2010; in press.
21. Kurbanov F, Tanaka Y, Fujiwara K et al. A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol 2005; 86: 2047-56.
22. Selabe S, Lukhwareni A, Song E et al. Mutations associated with lamivudine-resistance in therapy-naive HBV-infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007; 79: 1650-4.